AssetMark Inc’s Viridian Therapeutics VRDN Stock Holding History

AssetMark Inc’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$288	Buy	+14	New	+$299	﹤0.01%	3548

Other funds holding VRDN

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

AMI Asset Management Los Angeles, California $1.74B AUM 24.77% 1-Year Est. Return

OpenArc Corporate Advisory Atlanta, Georgia $8.86B AUM 19.31% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

Root Financial Partners Encinitas, California $2.98B AUM 13.9% 1-Year Est. Return

Owl Creek Wealth Partners Denver, Colorado $355M AUM

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

AssetMark Inc's VRDN Position: Q3 2026 in Review

AssetMark Inc opened a new position in Viridian Therapeutics (VRDN) in Q3 2026: 14 shares worth $288. The stake represents ﹤0.01% of the portfolio and ranks #3548 among its holdings.

12 funds tracked by Wall St. Rank hold VRDN as of Q3 2026.

AssetMark Inc held 14 shares of Viridian Therapeutics worth $288 as of Q3 2026.
Viridian Therapeutics was a new AssetMark Inc position in Q3 2026.
Viridian Therapeutics made up ﹤0.01% of AssetMark Inc's portfolio in Q3 2026, its #3548 holding.
12 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2026.

Based on AssetMark Inc's 13F filing for Q3 2026, filed 21 Oct 2026.